GYRE Relative Valuation
GYRE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GYRE is overvalued; if below, it's undervalued.
Historical Valuation
Gyre Therapeutics Inc (GYRE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 6.04. The fair price of Gyre Therapeutics Inc (GYRE) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：6.92
Fair
0.00
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Gyre Therapeutics Inc. (GYRE) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.00
EV/EBIT
Gyre Therapeutics Inc. (GYRE) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 1.64. The thresholds are as follows: Strongly Undervalued below -9.11, Undervalued between -9.11 and -3.74, Fairly Valued between 7.02 and -3.74, Overvalued between 7.02 and 12.39, and Strongly Overvalued above 12.39. The current Forward EV/EBIT of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Gyre Therapeutics Inc. (GYRE) has a current PS of 0.00. The 5-year average PS is 0.59. The thresholds are as follows: Strongly Undervalued below -3.28, Undervalued between -3.28 and -1.34, Fairly Valued between 2.53 and -1.34, Overvalued between 2.53 and 4.46, and Strongly Overvalued above 4.46. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
12.24
P/OCF
Gyre Therapeutics Inc. (GYRE) has a current P/OCF of 12.24. The 5-year average P/OCF is 4.25. The thresholds are as follows: Strongly Undervalued below -12.19, Undervalued between -12.19 and -3.97, Fairly Valued between 12.47 and -3.97, Overvalued between 12.47 and 20.69, and Strongly Overvalued above 20.69. The current Forward P/OCF of 12.24 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Gyre Therapeutics Inc. (GYRE) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Gyre Therapeutics Inc (GYRE) has a current Price-to-Book (P/B) ratio of 9.03. Compared to its 3-year average P/B ratio of -8.31 , the current P/B ratio is approximately -208.70% higher. Relative to its 5-year average P/B ratio of -8.31, the current P/B ratio is about -208.70% higher. Gyre Therapeutics Inc (GYRE) has a Forward Free Cash Flow (FCF) yield of approximately -1.47%. Compared to its 3-year average FCF yield of -0.09%, the current FCF yield is approximately 1497.55% lower. Relative to its 5-year average FCF yield of -0.09% , the current FCF yield is about 1497.55% lower.
8.90
P/B
Median3y
-8.31
Median5y
-8.31
-1.39
FCF Yield
Median3y
-0.09
Median5y
-0.09
Competitors Valuation Multiple
The average P/S ratio for GYRE's competitors is 31.12, providing a benchmark for relative valuation. Gyre Therapeutics Inc Corp (GYRE) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -18.82%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of GYRE decreased by 49.75% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 271.98 to 333.88.
The secondary factor is the Revenue Growth, contributed -18.82%to the performance.
Overall, the performance of GYRE in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Gyre Therapeutics Inc (GYRE) currently overvalued or undervalued?
What is Gyre Therapeutics Inc (GYRE) fair value?
How does GYRE's valuation metrics compare to the industry average?
What is the current P/B ratio for Gyre Therapeutics Inc (GYRE) as of Aug 07 2025?
What is the current FCF Yield for Gyre Therapeutics Inc (GYRE) as of Aug 07 2025?
What is the current Forward P/E ratio for Gyre Therapeutics Inc (GYRE) as of Aug 07 2025?